Building on the new structure, the company’s 2026 objectives include: CDMO Platform: Scaling operations across both sites and expanding the customer base in the U.S. and Europe; Leveraging the Recipharm collaboration to support programs beyond early-stage development; Targeting approximately $5 million in CDMO revenues in 2026. R&D: Advancing PC111 as the company’s lead value-driving program; Progressing the IL-17 undisclosed second target bi-specific program as a key validation of the NanoAbs platform; Continuing to advance the pipeline through capital-efficient strategies, with a focus on non-dilutive funding to support early-stage development.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCNI:
- Scinai Immunotherapeutics Revises €12M FENG Bid and Extends PinCell Option Timeline
- Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Deficiency, Given Until September to Regain Compliance
- Scinai Immunotherapeutics highlights expanded CDMO platform
- Scinai Immunotherapeutics signs second amendment to PinCell option agreement
- Scinai Wins Expanded Israel Innovation Authority Backing for Robotic Aseptic Platform